Therapeutic T cell engineering

[1]  M. Baker,et al.  Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. , 2019, The Journal of clinical investigation.

[2]  F. Watt,et al.  Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[4]  J. Mcclendon.  “Race” to the Finish Line , 2017 .

[5]  Bruce L Levine,et al.  PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. , 2017, Blood.

[6]  Adrian J. Thrasher,et al.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.

[7]  Emily R. Levy,et al.  Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity , 2017, Nature Medicine.

[8]  R. O'Regan,et al.  Anti-CD22 CAR Therapy Leads to ALL Remissions. , 2017, Cancer discovery.

[9]  C. June,et al.  Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms , 2017, Leukemia.

[10]  J. Wolchok,et al.  An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity , 2017, Molecular therapy oncolytics.

[11]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[12]  A. Ball,et al.  A Novel Phase-Change Hydrogel Substrate for T Cell Activation Promotes Increased Expansion of CD8+ Cells Expressing Central Memory and Naive Phenotype Markers , 2016 .

[13]  P. Porter,et al.  Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues , 2016, Clinical Cancer Research.

[14]  D. Busch,et al.  Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. , 2016, The Journal of clinical investigation.

[15]  J. Wolchok,et al.  T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Syed Abbas Ali,et al.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. , 2016, Blood.

[17]  S. Rosenberg,et al.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[19]  C. Arrowsmith,et al.  BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. , 2016, The Journal of clinical investigation.

[20]  M. Baker,et al.  Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. , 2016, The Journal of clinical investigation.

[21]  Yang Feng,et al.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. , 2016, The Journal of clinical investigation.

[22]  M. Sabatino,et al.  Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. , 2016, Blood.

[23]  A. Lanzavecchia,et al.  Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease , 2016, Science.

[24]  Yong-Chen Lu,et al.  Targeting neoantigens for cancer immunotherapy. , 2016, International immunology.

[25]  M. Jensen,et al.  ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells , 2016, Cancer Immunology Research.

[26]  Krishnendu Roy,et al.  Biomanufacturing of Therapeutic Cells: State of the Art, Current Challenges, and Future Perspectives. , 2016, Annual review of chemical and biomolecular engineering.

[27]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[28]  S. Quezada,et al.  TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. , 2016, Cancer research.

[29]  Y. Chen,et al.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells , 2016, Cancer Immunology Research.

[30]  R. O'reilly,et al.  Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections , 2016, Bone Marrow Transplantation.

[31]  T. Fry,et al.  Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. , 2016, Blood.

[32]  Brian Keith,et al.  Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.

[33]  J. Bluestone,et al.  Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease , 2016, Nature Reviews Immunology.

[34]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[35]  V. Buchholz,et al.  Role of memory T cell subsets for adoptive immunotherapy. , 2016, Seminars in immunology.

[36]  Michel Sadelain,et al.  Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. , 2016, Cancer discovery.

[37]  M. Sadelain,et al.  The quest for spatio-temporal control of CAR T cells , 2015, Cell Research.

[38]  Wendell A. Lim,et al.  Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.

[39]  M. Sadelain,et al.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.

[40]  A. Heimberger,et al.  Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. , 2015, Cancer research.

[41]  Alexandria P. Cogdill,et al.  Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. , 2015, Cancer research.

[42]  Michel Sadelain,et al.  CAR therapy: the CD19 paradigm. , 2015, The Journal of clinical investigation.

[43]  J. E. Brewer,et al.  NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.

[44]  Michel Sadelain,et al.  The pharmacology of second-generation chimeric antigen receptors , 2015, Nature Reviews Drug Discovery.

[45]  M. Sadelain,et al.  Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition , 2015, PloS one.

[46]  R. Krance,et al.  Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. , 2015, Blood.

[47]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[48]  Michel Sadelain,et al.  New cell sources for T cell engineering and adoptive immunotherapy. , 2015, Cell stem cell.

[49]  S. Riddell,et al.  Designing chimeric antigen receptors to effectively and safely target tumors. , 2015, Current opinion in immunology.

[50]  David M Kranz,et al.  TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. , 2015, Current opinion in immunology.

[51]  Ton N. Schumacher,et al.  Adoptive cellular therapy: A race to the finish line , 2015, Science Translational Medicine.

[52]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Na Li,et al.  Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.

[54]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[55]  X. Wang,et al.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies , 2015, Cancer Gene Therapy.

[56]  R. Orentas,et al.  Towards a commercial process for the manufacture of genetically modified T cells for therapy , 2015, Cancer Gene Therapy.

[57]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[58]  T. Laurell,et al.  Separation of Lymphocyte Populations from Peripheral Blood Progenitor Cell Products Using Affinity Bead Acoustophoresis , 2014 .

[59]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[60]  Z. Eshhar,et al.  Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody–Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds , 2014, The Journal of Immunology.

[61]  M. Kester,et al.  Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. , 2014, Blood.

[62]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[63]  D. Kranz,et al.  A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control , 2014, Cancer Immunology, Immunotherapy.

[64]  M. Smyth,et al.  Targeting cancer-derived adenosine: new therapeutic approaches. , 2014, Cancer discovery.

[65]  Christian Stemberger,et al.  Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. , 2014, Immunity.

[66]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[67]  Z. Eshhar,et al.  Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  D. Atanackovic,et al.  TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer , 2014, Gene Therapy.

[69]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[70]  Xiaomin Wang,et al.  Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor , 2014, Scientific Reports.

[71]  Harjeet Singh,et al.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19 , 2014, Immunological reviews.

[72]  D. Farber,et al.  Human memory T cells: generation, compartmentalization and homeostasis , 2013, Nature Reviews Immunology.

[73]  N. Emi,et al.  Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H , 2013, Gene Therapy.

[74]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[75]  Sadik H. Kassim,et al.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.

[76]  Michel Sadelain,et al.  PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.

[77]  B. Lipkens,et al.  The Concentration and Separation Of Blood Components Using Acoustic Radiation Force , 2013 .

[78]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[79]  N. Restifo,et al.  Reassessing target antigens for adoptive T cell therapy , 2013, Nature Biotechnology.

[80]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[81]  Mithat Gonen,et al.  Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy , 2013, Nature Biotechnology.

[82]  Bent K Jakobsen,et al.  Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells , 2013, Science Translational Medicine.

[83]  M. Smyth,et al.  Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells , 2013, Clinical Cancer Research.

[84]  S. Pai,et al.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. , 2013, Blood.

[85]  Joost B. Beltman,et al.  Heterogeneous Differentiation Patterns of Individual CD8+ T Cells , 2013, Science.

[86]  Thomas Höfer,et al.  Disparate Individual Fates Compose Robust CD8+ T Cell Immunity , 2013, Science.

[87]  S. Riddell,et al.  Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells , 2013, Clinical Cancer Research.

[88]  Michel Sadelain,et al.  CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia , 2013, PloS one.

[89]  B. Levine,et al.  T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans , 2013, Cancer Immunology Research.

[90]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[91]  I. Pastan,et al.  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. , 2013, Blood.

[92]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[93]  S. Bicciato,et al.  IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. , 2013, Blood.

[94]  M. Raffeld,et al.  B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma , 2013, Clinical Cancer Research.

[95]  Hiroshi Kawamoto,et al.  Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. , 2013, Cell stem cell.

[96]  Haruhiko Koseki,et al.  Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. , 2013, Cell stem cell.

[97]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[98]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[99]  C. Klebanoff,et al.  Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.

[100]  J. Gribben,et al.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. , 2012, Blood.

[101]  S. Forman,et al.  Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. , 2012, Molecular immunology.

[102]  Luigi Naldini,et al.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. , 2012, Blood.

[103]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[104]  Christian Stemberger,et al.  Novel Serial Positive Enrichment Technology Enables Clinical Multiparameter Cell Sorting , 2012, PloS one.

[105]  S. Eccles,et al.  Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling , 2012, Journal of Clinical Immunology.

[106]  T. Gajewski,et al.  Cancer immunotherapy , 2012, Molecular oncology.

[107]  Lei Zhang,et al.  Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer , 2012, Nature Medicine.

[108]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[109]  D. Munn.  Blocking IDO activity to enhance anti-tumor immunity. , 2012, Frontiers in bioscience.

[110]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[111]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[112]  H. Shiku,et al.  Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. , 2011, Blood.

[113]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[114]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[115]  M. Sadelain,et al.  In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. , 2011, Cancer research.

[116]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[117]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  Egbert Oosterwijk,et al.  Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. , 2011, Blood.

[119]  P. Darcy,et al.  Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. , 2011, Immunotherapy.

[120]  J. Melenhorst,et al.  Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. , 2010, Blood.

[121]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[122]  S. Rosenberg,et al.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.

[123]  R. Morgan,et al.  Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition , 2010, The Journal of Immunology.

[124]  M. Sadelain,et al.  IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. , 2010, Blood.

[125]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[126]  S. Rosenberg,et al.  Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells , 2010, Journal of immunotherapy.

[127]  Yun Ji,et al.  Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity , 2009, Proceedings of the National Academy of Sciences.

[128]  F. Timmermans,et al.  Generation of T Cells from Human Embryonic Stem Cell-Derived Hematopoietic Zones1 , 2009, The Journal of Immunology.

[129]  V. Cerundolo,et al.  Rational development of high-affinity T-cell receptor-like antibodies , 2009, Proceedings of the National Academy of Sciences.

[130]  Michel Sadelain,et al.  The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.

[131]  G. Schuler,et al.  Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer , 2009, Gene Therapy.

[132]  Michel Sadelain,et al.  Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors , 2008, Nature Biotechnology.

[133]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[134]  P. Romero,et al.  Molecular Design of the Cαβ Interface Favors Specific Pairing of Introduced TCRαβ in Human T Cells1 , 2008, The Journal of Immunology.

[135]  M. Sadelain,et al.  T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection , 2007, Nature Medicine.

[136]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  S. Rosenberg,et al.  High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[138]  Ming C. Wu,et al.  Massively parallel manipulation of single cells and microparticles using optical images , 2005, Nature.

[139]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[140]  D. Baltimore,et al.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[141]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated into One Combined CD28/CD3ζ Signaling Receptor Molecule , 2004, The Journal of Immunology.

[142]  J. Blattman,et al.  Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer cell.

[143]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[144]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[145]  N. A. MITCttlSON.  STUDIES ON THE IMMUNOLOGICAL RESPONSE TO FOREIGN TUMOR TRANSPLANTS IN THE MOUSE , 2003 .

[146]  C. Macken,et al.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[147]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 , 2001, The Journal of Immunology.

[148]  T. Brocker.  Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells , 2000 .

[149]  T. Brocker.  Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. , 2000, Blood.

[150]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[151]  N. Bander,et al.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. , 1999, Neoplasia.

[152]  M. Sadelain,et al.  Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes , 1998, The Journal of experimental medicine.

[153]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[154]  S. Hanauer,et al.  New therapeutic approaches. , 1995, Gastroenterology clinics of North America.

[155]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[156]  Klaus Rajewsky,et al.  Impairment of T-cell-dependent B-cell responses and B-l cell development in CD19-deficient mice , 1995, Nature.

[157]  B. Koller,et al.  Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. , 1995, Immunity.

[158]  K. Karjalainen,et al.  Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes , 1995, The Journal of experimental medicine.

[159]  S. Riddell,et al.  Principles for adoptive T cell therapy of human viral diseases. , 1995, Annual review of immunology.

[160]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[161]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[162]  K. Karjalainen,et al.  New simplified molecular design for functional T cell receptor , 1993, European journal of immunology.

[163]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[164]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[165]  M. Davis,et al.  Molecular components of T-cell recognition. , 1992, Annual review of immunology.

[166]  L. Old.  Tumor immunology: the first century. , 1992, Current opinion in immunology.

[167]  C. Melief,et al.  Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. , 1992, Advances in cancer research.

[168]  R. Klausner,et al.  T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[169]  Arthur Weiss,et al.  The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways , 1991, Cell.

[170]  B. Seed,et al.  Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides , 1991, Cell.

[171]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[172]  A. Miller.  Retrovirus packaging cells. , 1990, Human gene therapy.

[173]  S. Burakoff.  Graft-vs.-host disease : immunology, pathophysiology, and treatment , 1990 .

[174]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[175]  J. McCubrey,et al.  Transfer of specificity by murine alpha and beta T-cell receptor genes. , 1986, Nature.

[176]  S. Rosenberg,et al.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. , 1986, Annual review of immunology.

[177]  J. Selkon,et al.  β-LACTAMASE-PRODUCING ANÆROBES , 1980, The Lancet.

[178]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[179]  J. Miller,et al.  Immunological function of the thymus. , 1961, Lancet.

[180]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[181]  P T PHILLIPS,et al.  The first century. , 1959, Journal of the American Dental Association.